Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
复制标题
DOI：
10.1200/jco.2005.04.7373
复制
发表时间：
2006-03-20
影响因子：
45.3
通讯作者：
Alberts, DS
中科院分区：
文献类型：
--
作者：
Markmann, M;Liu, PY;Alberts, DS
先前的一份报告表明，在CA-125达到正常化的卵巢癌患者组中，最低血清CA-125水平可以准确地定义复发的风险。使用类似的CA-125亚组，我们试图确定在初始化疗达到临床定义的完全缓解的女性开始维持化疗前的基线CA-125水平是否具有预后价值。患者和方法本回顾性分析中纳入的患者接受了先前报道的两项维持性化疗试验中的一项（3个或1个2个月周期的紫杉醇；口服阿特胺），基线CA-125水平为
PurposeA previous report suggested the nadir serum CA-125 level within the group of patients with ovarian cancer who achieved normalization of CA-125 accurately defined the risk of relapse. Using similar CA-125 subgroups, we sought to determine if the baseline CA-125 level before initiation of maintenance chemotherapy in women achieving a clinically-defined complete response to primary chemotherapy would be of prognostic value.Patients and MethodsPatients included in this retrospective analysis had been treated on one of two previously reported trials of maintenance chemotherapy (three v 1 2-monthly cycles of paclitaxel; oral altretamine), with a baseline CA-125 level of